Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

A New Sulpha Compound ("6257") and its Use in Human Cholera Infection

Abstract

IT was observed by one of us (S. S. B.) in 1939 that hexa-methylene-tetra-amine, in a 10 per cent solution in normal saline, killed cholera vibrio in less than half an hour up to a concentration of 1012. Although interrupted by conditions of field service, efforts resulted in the production of three crude compounds of hexamine linkage to para-aminobenzene sulphonamide, experiments with which, on animal and human cholera infection, gave hope of successful chemotherapy against Asiatic cholera. A chance discussion with the scientific department of C.I.B.A. (Basle) resulted in our obtaining a condensation product—"6257"—of two molecules of 2 p-amino-benzene sulphonamido-thiazole (‘Cibazol') and three molecules of formaldehyde with the formula C21H22O6N6S4 (the actual constitution not having yet been worked out) and molar weight much greater than that of any other sulpha compound so far employed in clinical therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

BHATNAGAR, S., FERNANDES, F., SA, J. et al. A New Sulpha Compound ("6257") and its Use in Human Cholera Infection. Nature 161, 395–396 (1948). https://doi.org/10.1038/161395b0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/161395b0

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing